502 related articles for article (PubMed ID: 31371478)
1. Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor.
Taniguchi T; Ashizawa N; Matsumoto K; Saito R; Motoki K; Sakai M; Chikamatsu N; Hagihara C; Hashiba M; Iwanaga T
J Pharmacol Exp Ther; 2019 Oct; 371(1):162-170. PubMed ID: 31371478
[TBL] [Abstract][Full Text] [Related]
2. Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone.
Ahn SO; Ohtomo S; Kiyokawa J; Nakagawa T; Yamane M; Lee KJ; Kim KH; Kim BH; Tanaka J; Kawabe Y; Horiba N
J Pharmacol Exp Ther; 2016 Apr; 357(1):157-66. PubMed ID: 26907620
[TBL] [Abstract][Full Text] [Related]
3. Hypouricemic agents reduce indoxyl sulfate excretion by inhibiting the renal transporters OAT1/3 and ABCG2.
Taniguchi T; Omura K; Motoki K; Sakai M; Chikamatsu N; Ashizawa N; Takada T; Iwanaga T
Sci Rep; 2021 Mar; 11(1):7232. PubMed ID: 33790363
[TBL] [Abstract][Full Text] [Related]
4. Uricosuric Agents Affect Plasma and Kidney Concentration of Adefovir via Inhibition of Oat1 and Mrp2 in Rats.
Motoki K; Taniguchi T; Ashizawa N; Sakai M; Chikamatsu N; Yamano K; Iwanaga T
Biol Pharm Bull; 2023; 46(2):170-176. PubMed ID: 36724945
[TBL] [Abstract][Full Text] [Related]
5. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
Miner JN; Tan PK; Hyndman D; Liu S; Iverson C; Nanavati P; Hagerty DT; Manhard K; Shen Z; Girardet JL; Yeh LT; Terkeltaub R; Quart B
Arthritis Res Ther; 2016 Oct; 18(1):214. PubMed ID: 27716403
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological properties and clinical efficacy of dotinurad (URECE
Taniguchi T; Ashizawa N
Nihon Yakurigaku Zasshi; 2020; 155(6):426-434. PubMed ID: 33132262
[TBL] [Abstract][Full Text] [Related]
7. A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease.
Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
Cells; 2024 Mar; 13(5):. PubMed ID: 38474414
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study.
Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):53-61. PubMed ID: 31792640
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study.
Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):44-52. PubMed ID: 31754882
[TBL] [Abstract][Full Text] [Related]
10. Ideal pharmacokinetic profile of dotinurad as a selective urate reabsorption inhibitor.
Omura K; Miyata K; Kobashi S; Ito A; Fushimi M; Uda J; Sasaki T; Iwanaga T; Ohashi T
Drug Metab Pharmacokinet; 2020 Jun; 35(3):313-320. PubMed ID: 32327267
[TBL] [Abstract][Full Text] [Related]
11. Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout.
Hosoya T; Fushimi M; Okui D; Sasaki T; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):80-91. PubMed ID: 31875931
[TBL] [Abstract][Full Text] [Related]
12. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
Kuriyama S
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):1-5. PubMed ID: 31754883
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study.
Osonoi T; Saito M; Hosoya M; Douguchi S; Ofuchi K; Katoh M
Front Endocrinol (Lausanne); 2022; 13():1042061. PubMed ID: 36714585
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Stereoselective Metabolism, Inhibitory Effect on Uric Acid Uptake Transporters, and Pharmacokinetics of Lesinurad Atropisomers.
Yang C; Zhou D; Shen Z; Wilson DM; Renner M; Miner JN; Girardet JL; Lee CA
Drug Metab Dispos; 2019 Feb; 47(2):104-113. PubMed ID: 30442650
[TBL] [Abstract][Full Text] [Related]
15. Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment.
Kumagai Y; Sakaki M; Furihata K; Ito T; Inoue K; Yoshida T; Matsumoto S; Furuno K; Hagino A
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):25-35. PubMed ID: 31760530
[TBL] [Abstract][Full Text] [Related]
16. Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor.
Fukase H; Okui D; Sasaki T; Fushimi M; Ohashi T; Hosoya T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):17-24. PubMed ID: 31823130
[TBL] [Abstract][Full Text] [Related]
17. Interactions of urate transporter URAT1 in human kidney with uricosuric drugs.
Shin HJ; Takeda M; Enomoto A; Fujimura M; Miyazaki H; Anzai N; Endou H
Nephrology (Carlton); 2011 Feb; 16(2):156-62. PubMed ID: 21272127
[TBL] [Abstract][Full Text] [Related]
18. Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2.
Toyoki D; Shibata S; Kuribayashi-Okuma E; Xu N; Ishizawa K; Hosoyamada M; Uchida S
Am J Physiol Renal Physiol; 2017 Sep; 313(3):F826-F834. PubMed ID: 28679589
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents.
Zhao Z; Liu J; Yuan L; Yang Z; Kuang P; Liao H; Luo J; Feng H; Zheng F; Chen Y; Wu T; Guo J; Cao Y; Yang Y; Lin C; Zhang Q; Chen J; Pang J
Eur J Med Chem; 2022 Nov; 242():114682. PubMed ID: 36001935
[TBL] [Abstract][Full Text] [Related]
20. Effect and mechanism of dioscin from Dioscorea spongiosa on uric acid excretion in animal model of hyperuricemia.
Zhang Y; Jin L; Liu J; Wang W; Yu H; Li J; Chen Q; Wang T
J Ethnopharmacol; 2018 Mar; 214():29-36. PubMed ID: 29233733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
